{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:36:16Z","timestamp":1787664976865,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proteinuria is associated with long-term kidney failure (KF) risk. In trials of CKD and diabetic kidney disease, urine albumin:creatinine ratio (ACR) has been the preferred urinary protein measurement and features in guidelines and risk-prediction models. In studies of rare, glomerular diseases, urine protein: creatinine ratio (PCR) has more often been used, consequently featuring in treatment algorithms for these diseases. While equations estimating ACR from PCR (estACR) have been developed in large CKD cohorts, whether ACR, PCR, non-albumin proteinuria, and estACR differ in their relationships with KF in patients with rare kidney diseases is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients in RaDaR with same-day ACR and PCR measurements were included. Analyses were undertaken for the whole cohort, and by disease subtype and ACR tertile. Calibration plots assessed the performance of converting PCR to ACR. Cox regression models of time to KF or death (adjusting for age, sex, eGFR, disease) were run with four proteinuria measures: ACR, PCR, non-albumin proteinuria and estACR. Model fit was assessed using AIC (Akaike information criterion) and SBC (Schwarz Bayesian information Criterion) values, ROC curves and time-dependent AUC, and concordance compared using Uno\u2019s\u00a0C statistic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 4156 patients, 717 (17%) experienced a KF or death event. At lower predicted ACR deciles, conversion of PCR to ACR underestimated true ACR. Very similar AIC and SBC statistics were observed for all proteinuria measurements, including estACR. Time-dependent AUC at 5 years were &amp;gt;0.83 for all models and disease sub-groups. No statistically significant differences in model concordance were seen (Chi2 \u00a0P\u00a0&amp;gt;\u00a0.2 for all comparisons). Within each ACR tertile, AIC, SBC, and AUC values were similar across all proteinuria metrics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cohort of patients with rare kidney diseases, across all levels of proteinuria studied, we identified no statistically significant differences in the performance of ACR, PCR, non-albumin proteinuria, or estACR to predict KF risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag066","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:47:07Z","timestamp":1774529227000},"page":"ii30-ii40","source":"Crossref","is-referenced-by-count":1,"title":["Association of UACR and UPCR with kidney failure: analysis of observational data in patients with rare kidney diseases"],"prefix":"10.1093","volume":"41","author":[{"given":"Katie","family":"Wong","sequence":"first","affiliation":[{"name":"Centre for Kidney and Bladder Health, University College London ,","place":["UK"]},{"name":"National Registry of Rare Kidney Diseases, UK Kidney Association , Bristol ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pitcher","sequence":"additional","affiliation":[{"name":"Centre for Kidney and Bladder Health, University College London ,","place":["UK"]},{"name":"National Registry of Rare Kidney Diseases, UK Kidney Association , Bristol ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[{"name":"Mayer IgA Nephropathy Laboratories, University of Leicester , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-1579","authenticated-orcid":false,"given":"Daniel P","family":"Gale","sequence":"additional","affiliation":[{"name":"Centre for Kidney and Bladder Health, University College London ,","place":["UK"]},{"name":"National Registry of Rare Kidney Diseases, UK Kidney Association , Bristol ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RaDaR","family":"Consortium","sequence":"additional","affiliation":[{"name":"Multiple Affiliations"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"2026082423263134000_bib1","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.2215\/CJN.09741110","article-title":"Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes","volume":"6","author":"Bello","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026082423263134000_bib2","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Chronic kidney disease prognosis consortium: association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"2026082423263134000_bib3","first-page":"8","article-title":"Chronic Kidney Disease: assessment and management","year":"2021","journal-title":"NICE guideline (NG203)"},{"key":"2026082423263134000_bib4","doi-asserted-by":"crossref","first-page":"e1002955","DOI":"10.1371\/journal.pmed.1002955","article-title":"The kidney failure risk equation for prediction of end stage renal disease in UK primary care: an external validation and clinical impact projection cohort study","volume":"16","author":"Major","year":"2019","journal-title":"PLoS Med"},{"key":"2026082423263134000_bib5","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA"},{"key":"2026082423263134000_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and European medicines agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026082423263134000_bib7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026082423263134000_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Group TE-KC.","year":"2023;","journal-title":"N Engl J Med"},{"key":"2026082423263134000_bib9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082423263134000_bib10","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"2026082423263134000_bib11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK national registry of rare kidney diseases (RaDaR) cohort","volume":"403","author":"Wong","year":"2024","journal-title":"Lancet"},{"key":"2026082423263134000_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","article-title":"Sparsentan: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"2026082423263134000_bib13","article-title":"Novartis receives FDA accelerated approval for Vanrafia\u00ae (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)"},{"key":"2026082423263134000_bib14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082423263134000_bib15","article-title":"FDA Approves Apellis\u2019 EMPAVELI\u00ae (pegcetacoplan) as the first C3G and primary IC-MPGN treatment for patients 12 and older\u2014Apellis Pharmaceuticals, Inc","journal-title":"webpage reference (Novartis)"},{"key":"2026082423263134000_bib16","article-title":"FDA approves first treatment for adults with complement 3 glomerulopathy, a rare kidney disease, to reduce proteinuria","journal-title":"FDA"},{"key":"2026082423263134000_bib17","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2019060605","article-title":"Estimating urine albumin-to-creatinine ratio from protein-to-creatinine ratio: development of equations using same-day measurements","author":"Weaver","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026082423263134000_bib18","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1681\/ASN.2020050707","article-title":"Authors\u2019 reply","volume":"31","author":"Weaver","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026082423263134000_bib19","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1681\/ASN.2020050545","article-title":"The estimation formula for the urinary albumin-creatinine ratio based on the protein-creatinine ratio are not valid for a kidney transplant and a living donor cohort","volume":"31","author":"Jehn","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026082423263134000_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/ndt\/gfad195","article-title":"Proteinuria, measured or estimated albuminuria for risk prediction in patients with chronic kidney disease?","volume":"39","author":"Kim","year":"2024","journal-title":"Nephrol Dialysis Transplant\u202f"},{"key":"2026082423263134000_bib21","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1093\/ndt\/gfq140","article-title":"Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio","volume":"25","author":"Methven","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2026082423263134000_bib22","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.ekir.2024.04.062","article-title":"Description and cross-sectional analyses of 25,880 adults and children in the UK national registry of rare kidney diseases cohort","volume":"9","author":"Wong","year":"2024","journal-title":"Kidney International Reports"},{"key":"2026082423263134000_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2019060605","article-title":"Estimating urine albumin-to-creatinine ratio from protein-to-creatinine ratio: development of equations using same-day measurements","volume":"31","author":"Weaver","year":"2020","journal-title":"JASN"},{"key":"2026082423263134000_bib24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.0006-341X.2005.030814.x","article-title":"Survival model predictive accuracy and ROC curves","volume":"61","author":"Heagerty","year":"2005","journal-title":"Biometrics"},{"key":"2026082423263134000_bib25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/sim.4154\/","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"key":"2026082423263134000_bib26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026082423263134000_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/pdi.2386","article-title":"Measurement of urine protein","volume":"39","author":"Ramsden","year":"2022","journal-title":"Pract Diabetes"},{"key":"2026082423263134000_bib28","doi-asserted-by":"crossref","first-page":"2461966","DOI":"10.1080\/23995270.2025.2461966","article-title":"Sparsentan clinical trials in glomerular diseases: defining endpoints and a path forward in light of the parasol initiative","volume":"5","author":"Trachtman","year":"2025","journal-title":"Future Rare Dis"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag066\/67602953\/gfag066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/Supplement_2\/ii30\/67602953\/gfag066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/Supplement_2\/ii30\/67602953\/gfag066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:26:44Z","timestamp":1787628404000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/Supplement_2\/ii30\/8551339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":28,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2026,3,27]]},"published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag066","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,27]]}}}